Pyxis Oncology Inc (PYXS) Stock Price, Quote & News

Company Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 cl...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 453 3596

Website: www.pyxisoncology.com

Address:

321 Harrison Avenue, 11th Floor, Suite 1, Boston, United States

BioTechHealthX Jun. 19 at 6:26 AM

$PYXS Analysts are bullish on Pyxis despite the dip. See why Jefferies, RBC, and H.C. Wainwright are betting big on this cancer-fighting biotech. https://biotechhealthx.com/biotech-news/this-1-stock-has-a-6-price-target-is-pyxis-pyxs-the-best-cheap-biotech-play-right-now/

0 · Reply

Bullbear1010101 Jun. 19 at 1:23 AM

$PYXS dip from 1.41. i knew it was to ready to go up. no news , no change in ownership, no pump yet or maybe ever

1 · Reply

savemefrom925 Jun. 17 at 7:09 PM

$PYXS bought 100 shares, will hold for a very long time.

0 · Reply

Cashholdem Jun. 13 at 1:43 PM

$PYXS

1 · Reply

Npapa1 Jun. 11 at 12:44 PM

$PYXS XBI is flying buy PYXS small caps are starting to move up also TNA

1 · Reply

Npapa1 Jun. 10 at 9:11 PM

$PYXS after hours $1.39 on decent volume

1 · Reply

Npapa1 Jun. 10 at 1:54 PM

$PYXS $1.41 and rising to 200 moving average https://stockcharts.com/sc3/ui/?s=PYXS

0 · Reply

Npapa1 Jun. 9 at 3:20 PM

$PYXS XBI is still going higher and biotechs are breaking out PYXS hit $1.39 this morning it’s now $1.33 it’s a buy at this price it’s over it’s 59 day moving average next level is 200 day

0 · Reply

Frapples5555 Jun. 9 at 2:27 PM

$PYXS good news will easily make this go past $3 and stay there.

0 · Reply

Rohtan Jun. 6 at 8:34 PM

$PYXS very nice close

1 · Reply

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 7:30 AM EDT - 5 weeks ago

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Apr 25, 2025, 1:17 PM EDT - 2 months ago

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Apr 2, 2025, 7:30 AM EDT - 2 months ago

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Mar 25, 2025, 4:30 PM EDT - 3 months ago

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Mar 18, 2025, 7:30 AM EDT - 3 months ago

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:30 AM EST - 3 months ago

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:30 AM EST - 4 months ago

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Feb 4, 2025, 7:30 AM EST - 4 months ago

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Dec 19, 2024, 4:08 PM EST - 6 months ago

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Dec 7, 2024, 1:30 AM EST - 7 months ago

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Nov 21, 2024, 9:18 AM EST - 7 months ago

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Nov 20, 2024, 4:05 PM EST - 7 months ago

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Nov 8, 2024, 1:30 PM EST - 8 months ago

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Sep 13, 2024, 7:08 AM EDT - 10 months ago

Moment Of Truth Approaches For Pyxis Oncology

Aug 14, 2024, 4:05 PM EDT - 11 months ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Jul 29, 2024, 8:00 AM EDT - 11 months ago

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Jun 28, 2024, 4:30 PM EDT - 1 year ago

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

May 30, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

May 14, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

May 9, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Mar 27, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Mar 21, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Mar 7, 2024, 4:30 PM EST - 1 year ago

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Mar 5, 2024, 4:45 PM EST - 1 year ago

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Nov 7, 2023, 4:30 PM EST - 1 year ago

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Sep 27, 2023, 9:18 AM EDT - 1 year ago

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Sep 7, 2023, 8:09 AM EDT - 1 year ago

Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed

Aug 31, 2023, 4:01 PM EDT - 1 year ago

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Aug 23, 2023, 8:35 AM EDT - 1 year ago

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Aug 10, 2023, 2:56 PM EDT - 2 years ago

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

Jul 10, 2023, 3:01 AM EDT - 2 years ago

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

Jun 15, 2023, 8:20 AM EDT - 2 years ago

Pyxis: Unique ADC Approach With A Catalyst In Late 2023

Jun 12, 2023, 2:59 AM EDT - 2 years ago

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

May 30, 2023, 10:52 PM EDT - 2 years ago

APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

May 30, 2023, 8:30 AM EDT - 2 years ago

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

May 24, 2023, 6:45 AM EDT - 2 years ago

Pyxis Oncology to Acquire Apexigen

May 11, 2023, 7:00 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

Mar 27, 2023, 7:32 AM EDT - 2 years ago

Pyxis Oncology: Cashed Up And Entering The Clinic

Mar 22, 2023, 6:45 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

Mar 16, 2023, 7:30 AM EDT - 2 years ago

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

Feb 13, 2023, 8:00 AM EST - 2 years ago

Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference

Dec 1, 2022, 6:45 AM EST - 2 years ago

Pyxis Oncology Announces FDA Clearance of Two IND Applications

Nov 1, 2022, 6:30 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update

BioTechHealthX Jun. 19 at 6:26 AM

0 · Reply

Bullbear1010101 Jun. 19 at 1:23 AM

$PYXS dip from 1.41. i knew it was to ready to go up. no news , no change in ownership, no pump yet or maybe ever

1 · Reply

savemefrom925 Jun. 17 at 7:09 PM

$PYXS bought 100 shares, will hold for a very long time.

0 · Reply

Cashholdem Jun. 13 at 1:43 PM

$PYXS

1 · Reply

Npapa1 Jun. 11 at 12:44 PM

$PYXS XBI is flying buy PYXS small caps are starting to move up also TNA

1 · Reply

Npapa1 Jun. 10 at 9:11 PM

$PYXS after hours $1.39 on decent volume

1 · Reply

Npapa1 Jun. 10 at 1:54 PM

$PYXS $1.41 and rising to 200 moving average https://stockcharts.com/sc3/ui/?s=PYXS

0 · Reply

Npapa1 Jun. 9 at 3:20 PM

$PYXS XBI is still going higher and biotechs are breaking out PYXS hit $1.39 this morning it’s now $1.33 it’s a buy at this price it’s over it’s 59 day moving average next level is 200 day

0 · Reply

Frapples5555 Jun. 9 at 2:27 PM

$PYXS good news will easily make this go past $3 and stay there.

0 · Reply

Rohtan Jun. 6 at 8:34 PM

$PYXS very nice close

1 · Reply

StockHunter75 Jun. 6 at 7:56 PM

$PYXS Bullish🐂🎯

0 · Reply

Rohtan Jun. 4 at 3:42 AM

$PYXS I like it quite here. It hasn’t started yet. Chart do not lie. I will come back if my theory of doubling the money here with this stock. Holding strong

1 · Reply

Npapa1 Jun. 3 at 1:53 PM

$PYXS biotechs are starting to move up watch XBI index which recently went over the 50 day moving average

0 · Reply

Npapa1 Jun. 2 at 1:04 PM

$PYXS Millennium Management LLC grew its position in Pyxis Oncology, Inc. (NASDAQ:PYXS - by 53.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,980,906 shares of the company's stock after purchasing an additional 1,043,228 shares during the period. Millennium Management LLC owned approximately 5.01% of Pyxis Oncology worth $4,650,000 at the end of the most recent quarter.

0 · Reply

Npapa1 Jun. 2 at 12:30 PM

$PYXS Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following upcoming investor. Jefferies Global Healthcare Conference in New York, NY on Thursday, June 5 at 4:55 p.m. ET

0 · Reply

Rohtan May. 29 at 8:06 PM

$PYXS waiting for a day when I wake up with 100% up hopefully

1 · Reply

the_real_Joker May. 29 at 3:55 PM

$PYXS ....

0 · Reply

TickrJunkie May. 28 at 6:53 PM

$PYXS Check out Zentek (ZTEK) — a Canadian nanotech innovator pushing the boundaries of graphene-based solutions. ZenGUARD: Advanced Antimicrobial Protection • Commercialization in Progress: Zentek is actively commercializing ZenGUARD, a patented graphene-based coating that enhances bacterial and viral filtration efficiency in surgical masks and HVAC filters. • Regulatory Milestone Achieved: ZenGUARD™ Enhanced Air Filters have completed 20-month shelf-life efficacy testing, maintaining consistent performance, and are now classified as a Class I medical device under Canadian regulations. • Market Adoption: The Forensic Services and Coroner’s Complex in Toronto has placed a purchase order for ZenGUARD™ Enhanced Air Filters, indicating growing market acceptance. ZenARMOR: Next-Gen Corrosion Protection • Innovative Development: ZenARMOR™ is a novel corrosion protection technology based on functionalized graphene oxide, offering superior performance and self-healing properties.

0 · Reply

Npapa1 May. 28 at 1:08 PM

$PYXS is today the day we finally break out?

0 · Reply

Rohtan May. 23 at 6:46 PM

$PYXS added more today. I can feel the pop

0 · Reply

Npapa1 May. 22 at 2:41 PM

$PYXS did you listen to the call yesterday and how positive the company is on the drug they are working on

2 · Reply

Rohtan May. 20 at 7:38 PM

$PYXS I love this company. Big payday imo in next 2 months or so.

1 · Reply

Market Cap	70.62M
Revenue (ttm)	16.15M
Net Income (ttm)	-77.33M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-478.82%
Debt to Equity Ratio	0.00

Volume	350,700
Avg Vol	463,184
Day's Range	N/A - N/A
Shares Out	61.95M
Stochastic %K	13%
Beta	1.18
Analysts	Strong Sell
Price Target	$6.20